Aussie doctors recommend MHT for bone health in under-65s with osteopenia
MHT to reduce fracture risk is recommended for women with a T-score of -1.8 or less.
Menopausal hormone therapy can be used to prevent fragility fractures in postmenopausal women under 65 with osteopenia, according to updated Australian guidance.
The Monash University–led menopause toolkit, first published in 2014, is the first to include advice on halting bone loss and reducing fracture risk in asymptomatic patients.
It states that menopausal hormone therapy (MHT) “should be considered” in all postmenopausal women with osteopenia before age 65 once other fracture risk factors have been considered.
First author and Melbourne endocrinologist Professor Susan Davis said the toolkit also included guidance on the use of dual-energy X-ray absorptiometry (DXA) in women with no history of minimal trauma fracture.
